A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Clinical trial NCT06065748 · RECRUITING
Trial details
- NCT number
- NCT06065748
- Sponsor
- Hoffmann-La Roche
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-11
- Primary completion
- 2027-02-19
- Enrollment
- 1050
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.